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Abstract
Background: Inherited epimutations of Mismatch Repair (MMR) genes are respon-
sible for Lynch Syndrome (LS) in a small, but well defined, subset of patients. 
Methylation of the MSH2 promoter consequent to the deletion of the upstream 
EPCAM gene is found in about 1%–3% of the LS patients and represents a classical 
secondary, constitutional and tissue‐specific epimutation. Several different EPCAM 
deletions have been reported worldwide, for the most part representing private vari-
ants caused by an Alu‐mediated recombination.
Methods: 712 patients with suspected LS were tested for MMR mutation in our 
Institute. EPCAM deletions were detected by multiplex ligation‐dependent probe 
amplification (MLPA) and then defined by Long‐Range polymerase chain reaction 
(PCR)/Sanger sequencing. A comprehensive molecular characterization of colorec-
tal cancer (CRC) tissues was carried out by immunohistochemistry of MMR pro-
teins, Microsatellite Instability (MSI) assay, methylation specific MLPA and 
transcript analyses. In addition, somatic deletions and/or variants were investigated 
by MLPA and next generation sequencing (NGS).
Results: An EPCAM deletion was found in five unrelated probands in Italy: variants 
c.556‐490_*8438del and c.858+1193_*5826del are novel; c.859‐1430_*2033del 
and c.859‐670_*530del were previously reported. All probands were affected by 
CRC at young age; tumors showed MSI and abnormal MSH2/MSH6 proteins ex-
pression. MSH2 promoter methylation, as well as aberrant in‐frame or out‐of‐frame 
EPCAM/MSH2 fusion transcripts, were detected in CRCs and normal mucosae.
Conclusion: An EPCAM deletion was the causative variant in about 2% of our insti-
tutional series of 224 LS patients, consistent with previously estimated frequencies. 
Early age and multiple CRCs was the main clinical feature of this subset of patients.
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1 |  INTRODUCTION
Pathogenic variants in MLH1, MSH2, MSH6 and PMS2 
Mismatch Repair (MMR) genes (OMIM: 120436, 609309, 
600678 and 600259) are causative of Lynch Syndrome 
(LS), an autosomal dominant condition that confers ele-
vated risk of developing colorectal cancer (CRC), endome-
trial cancer (EC) and several other types of cancer. Typical 
phenotypic features of LS tumors are Microsatellite 
Instability (MSI) and loss of MMR protein expression 
(Lynch et al., 2009).
Biallelic inactivation of one of MMR genes, as a result 
of combined germline and second hit somatic mutations, 
facilitates carcinogenesis. Nonsense, missense, frameshift 
and splicing variants, as well as deletions of one or more 
exons, are responsible for loss of function of the inherited, 
predisposing MMR allele. In addition, some so‐called epi-
mutations are reported. Epimutation is referred as a her-
itable change that does not alter the DNA sequence but 
affects gene expression via DNA methylation or histone 
modification. In LS, constitutional epimutations are mainly 
reported for the MLH1 gene, either as primary event arisen 
de novo in gametogenesis or as secondary event, caused 
by an in cis heritable genetic variant (Cini et al., 2015; 
Hitchins, 2013).
As about the MSH2 gene, a constitutional tissue‐spe-
cific promoter methylation can be inherited as secondary 
epimutation, due to a deletion involving the last exons of 
the EPCAM gene (OMIM: 185535) that maps upstream 
MSH2. As a consequence, EPCAM is brought close to 
MSH2 and, in EpCAM expressing tissues, a read‐through 
EPCAM/MSH2 fusion transcript is generated while the 
native MSH2 promoter is hypermethylated and silenced 
(Kovacs, Papp, Szentirmay, Otto, & Olah, 2009; Ligtenberg 
et al., 2009). This complex event represents the first hit in 
a well‐defined subset of LS patients (1%–3% of the total) 
(Kuiper et al., 2011) that are typified by the expression of 
aberrant EPCAM/MSH2 fusion transcripts in normal and 
tumor colon tissues (Kovacs et al., 2009; Ligtenberg et al., 
2009).
Several different EPCAM deletions have been described 
worldwide, in some cases as recurrent/founder mutations 
(Dymerska et al., 2017; Eguchi et al., 2016; Mur et al., 
2014; Spaepen et al., 2013). It has been established that the 
mechanism underlying these rearrangements is an Alu‐me-
diated deletion, involving different highly homologous Alu 
sequences that are interspersed in intronic and intergenic re-
gions within the EPCAM/MSH2 locus (Tutlewska, Lubinski, 
& Kurzawski, 2013).
Here we report on the identification and characteriza-
tion of four different EPCAM deletions in five unrelated 
Italian LS families, and their epigenetic effect on the 
MSH2 locus.
2 |  MATERIALS AND METHODS
From 1995 to 2017, DNA from a total of 712 unrelated 
cancer patients was collected in a diagnostic setting by the 
Functional Oncogenetics and Oncogenomics Laboratory at 
the CRO National Cancer Institute (Aviano, Italy). Patients 
were enrolled for genetic testing because of personal and 
family history consistent with LS and/or evidence of high 
MSI (MSI‐H) and/or negative for MMR protein according 
to immunohistochemistry (IHC). Diagnosis of LS was con-
firmed by MMR and EPCAM genetic testing in 224/712 
patients.
The genetic testing protocol and use of DNA samples for 
research purposes was approved by the Local Independent 
Ethics Committee (CRO‐15‐1997). Written informed con-
sent was obtained from all participants of the present study.
Mismatch Repair protein IHC was performed on 
Formalin‐Fixed and Paraffin‐Embedded (FFPE) sections, 
stained on the Ventana BenchMark Ultra platform (Ventana 
Medical Systems, Inc., Oro Valley AZ). MLH‐1 (M1), MSH2 
(G219‐1129), MSH6 (44) and PMS2 (EPR3947) (Roche 
Diagnostics, Indianapolis, IN) monoclonal antibodies were 
used to qualitatively identify human MMR proteins. Lesions 
were considered negative for protein expression when a com-
plete absence of nuclear staining was evident in tumor cells 
with concomitant nuclear staining of adjacent normal epithe-
lial and stromal cells.
Genetic screening for MMR genes was car-
ried out by Sanger sequencing of coding sequences 
(MSH2: NM_000251.2, MLH1: NM_000249.3, MSH6: 
NM_000179.2) and with SALSA® multiplex ligation‐ 
dependent probe amplification (MLPA)® probemixes P003 
(MLH1/MSH2), P072 (MSH6) and P248 (MLH1/MSH2 
confirmation), followed by copy number variation analysis 
with Coffalyser.net (MRC‐Holland, Amsterdam, Holland).
Long‐Range polymerase chain reactions (PCRs) for 
breakpoints detection were performed with Expand™ Long 
Template PCR System (Merck KGaA, Darmstadt, Germany). 
Shorter PCRs including breakpoints were obtained with 
GoTaq (Promega, Madison, WI) (primers and conditions 
available upon request). Polymerase chain reaction products 
were purified from agarose gel with the Wizard® SV Gel 
and PCR Clean‐Up System (Promega), then sequenced using 
a modified BigDye® cycle sequencing protocol (30x 94°C 
30″, 55°C 30″, 60°C 2′), to prevent secondary structures due 
to Alu‐mediated hybridization.
Tumor and normal mucosa methylation statuses were as-
sessed using Methylation Specific‐MLPA (MS‐MLPA) with 
SALSA® MLPA® ME011 MMR genes probemix (MRC‐
Holland). Blood DNA was used as a control.
Mutation analysis of tumor DNA was performed on the 
two available frozen CRC samples with a TruSeq Custom 
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Amplicon (Illumina, San Diego, CA) next generation se-
quencing (NGS) panel, including coding sequences of MSH2, 
MSH6 and MLH1 genes. Libraries were run on an Illumina 
MiSeq platform, with a mean coverage >4,000 reads. MLPA 
analysis for loss of heterozygosity (LOH) detection was 
carried out on frozen and FFPE tumor samples with the 
SALSA® MLPA® probemix P072‐C1 (MSH6).
Aberrant transcripts were investigated in RNAs extracted 
from frozen or FFPE samples. In brief, RNA from tumor 
and/or normal mucosa of carriers was purified with the 
TRIzol™ Reagent (ThermoFisher Scientific, Waltham, MA) 
or the RNeasy FFPE kit (Qiagen, Hilden, Germany) accord-
ing to manufacturer's protocols, and cDNA was retrotrans-
cribed using the SuperScript™ III Reverse Transcriptase 
(ThermoFisher Scientific) and random primers. The pres-
ence of fusion transcripts was evaluated by amplification 
and direct sequencing of PCRs covering different regions 
between exon 4 or 7 of the EPCAM gene and exon 1 or 2 or 
3 of MSH2 (primers and details upon request). The reference 
sequences NM_002354.2 and NG_012352.2 (EPCAM) and 
NM_000251.2 and NG_007110.2 (MSH2) were used for re-
porting aberrant transcripts and genomic deletions.
3 |  RESULTS
Of the 224 patients tested positive for LS in our laboratory 
from 1995 to 2017, five unrelated patients, all Italians, car-
ried a partial deletion of the EPCAM gene, involving exons 
6‐9 (families AV114 and UD18) or exons 8‐9 (families 
PD31, AV182 and PD78), as assessed by MLPA analyses. 
No other pathogenic variants were found in MSH2 and MSH6 
genes of these patients.
All probands were diagnosed with MSI‐H CRC at 
young age (34–50 years), and had a family history of CRC. 
Immunohistochemistry, performed on a representative tumor 
of the proband, revealed abnormal MSH2 and MSH6 expres-
sion (Table 1). Notably, besides tumors with clear‐cut loss 
T A B L E  1  EPCAM deletion carriers
Family ID Patient ID Sex
Clinical 
phenotype IHC MSH2/MSH6 MSI MSH2 methylation Somatic LOH
PD31 CFS394 F CRC 45 yb, 
55 y
H
CFS395a M CRC 43, 68 yb, 
duodenum 
62 y, larynxc 
67 y
−/Cytoplasmic H 33%(N) 23%(T) No
CFS890 M Healthy 37 y
CFS892 F Healthy 39 y
CFS918 F CRC 32 y, 
breastc 47 y
CFS919 F Healthy 44 y
CFS920 M Healthy 57 y




H 29%(N) 50%(T) EPCAM‐MSH2‐
MSH6 loss
CFS487 M CRC 42 yb Cytoplasmic/
cytoplasmic
H Not evaluable EPCAM‐MSH2‐
MSH6 loss
CFS488 F Healthy 35 y
CFS516 M CRC 25 yb H
UD18 CFS825a M CRC 39, 53 yb −/− H 23%(T) No
CFS913 M Healthy 19 y
CFS914 M Healthy 21 y
AV182 CFS1043a M CRC 50, 50, 
63 yb
−/− H 23%(T) EPCAM loss
PD78 CFS1475a M CRC 34 yb Focal/+ H 23%(T) No
CFS1541 M Healthy 39 y
Note. CRC, colorectal cancer; H, MSI‐H; IHC, immunoistochemistry; LOH, loss of heterozygosity; LS, Lynch Syndrome; MSI, microsatellite instability; N, normal 
mucosa; T, tumor; y, years (age of tumor onset, if affected, and age at registration, if healthy).
aProbands. bTumors tested. cTumors not included in LS spectrum. 
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F I G U R E  1  Representative molecular characterization of patient CFS396 carrying the EPCAM Del_16.5. (a) Immunohistochemistry showing 
that MSH2 protein is exclusively expressed in the cytoplasm of the tumor cells (H&E counterstain, O.M. 400x). (b) Sanger sequence of breakpoint. 
(c) Coffalyser analysis of methylation specific‐MLPA in tumor DNA, displaying MSH2 promoter methylation. (d) Coffalyser analysis of MLPA 
in tumor DNA, in which partial loss of heterozygosity of EPCAM is evidenced, due to a large somatic deletion involving also MSH2 and MSH6 
genes. (e) Agarose‐gel electrophoresis showing aberrant EPCAM/MSH2 fusion transcripts amplified from tumor (lane 1–2) and normal mucosa 
(lanes 3–4) cDNAs; DNA ladders: ΦX174  DNA‐Hae III Digest (left) and 100 bp ladder (right). Roman numerals indicate the main PCR products 
that were sequenced. (f) Sanger sequence of an in‐frame fusion transcript (corresponding to amplicon III). (g) Sanger sequence of an out‐of‐frame 
fusion transcript (amplicon I and V)
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of nuclear MSH2/MSH6 staining, one tumor retained focal 
MSH2 expression and some showed heterogeneous MSH2 
and/or MSH6 cytoplasmic staining (Figure 1a).
Twenty relatives from four families were tested for 
EPCAM deletion: eight healthy subjects (age 19–57 years) 
and four patients affected by early‐onset CRC (age 
25–45 years) tested positive at MLPA for the deletion de-
tected in the proband. Clinical and molecular data of all car-
riers are listed in Table 1.
Long range PCRs from carriers produced smaller ampli-
cons compared with wild‐type controls. Characterization of 
the breakpoints (Figure S1) revealed four different deletions, 
Del_4.9, Del_16.5 (Figure 1b), Del_2.6, Del_11.5 (Table 2), 
all residing in repetitive sequences and involving two Alu 
regions with very high homology (79%–88%); a microho-
mology sequence (from 9 to 36 bp) was identified for all the 
described deletions. Families AV114 and UD18 carried the 
same deletion.
Mismatch Repair gene methylation status was ascer-
tained in five tumors (CFS395T, CFS396T, CFS825T, 
CFS1043T, CFS1475T) and two normal mucosae (CFS395N 
and CFS396N). MSH2 promoter was methylated, at different 
percentages (23%–50%), in both normal and tumor tissues 
(Table 1 and Figure 1c).
No pathogenic variant acting as a second hit was found 
by NGS screening in either MSH2 or other MMR genes in 
the DNA from CFS395T and CFS396T tumors. MLPA per-
formed on available tumor samples highlighted a variegate 
pattern ranging from retention of the second EPCAM allele 
to LOH of various extent and amplitude (up to MSH2 and 
MSH6 loci) (Table 1 and Figure 1d).
Several EPCAM‐MSH2 fusion transcripts were detected 
by PCR in normal mucosa and in CRC samples CFS395T, 
CFS396T and CFS1475T (Table S1 and Figure 1e), but not 
in wild‐type controls (not shown).
Sequencing of PCR products evidenced at least five dif-
ferent aberrant transcripts originated from Del_16.5: three 
in‐frame and two creating a frameshift with a premature stop 
codon in exon 2 (Figure 1f‐g shows a representative case). 
Also Del_4.9 and Del_11.5 yielded different in‐frame and 
out‐of‐frame EPCAM/MSH2 fusion transcripts (Table 1).
4 |  DISCUSSION
An increasing body of evidence supports the relevance of 
epigenetic modifications in the pathogenesis of hereditary 
syndromes. The elucidation of the primary event causing the 
epigenetic change is crucial to ascertain the actual second-
ary nature of the epimutation and to optimize cascade testing 
in family members. In the context of LS testing, the impor-
tance of epimutations analysis is universally recognized and 
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10 years many different variants of this gene have been de-
scribed; however, construction of a complete and curated 
public database for EPCAM deletions is still in progress 
(https://databases.lovd.nl/shared/genes/EPCAM), and the 
actual frequency of EPCAM mutations in LS is poorly de-
fined. In particular, no precise estimate of EPCAM variant 
incidence in the Italian LS population is available so far. Our 
institutional database includes 224 molecularly confirmed 
LS unrelated families, five of which with EPCAM deletion 
(>2%), a frequency consistent with literature data (Tutlewska 
et al., 2013).
All EPCAM deletions reported worldwide are bona 
fide Alu recombination‐mediated variants, as they are the 
four deletions presented here. With the exception of few 
founder mutations identified in the Netherlands and Poland 
(Dymerska et al., 2017; Niessen et al., 2009), in general 
deletions in the EPCAM gene are rare, sometimes private, 
variants with no recombination hotspot sites. Two of the 
four deletions (Del_16.5 and Del_11.5) that we describe 
here are novel, not recorded in any databases or literature. 
The Del_2.6 variant was identical to that reported in the 
Netherlands (Kuiper et al., 2011). The Del_4.9 variant 
was first described as founder mutation in Dutch popula-
tion and in the large American Family R (Kuiper et al., 
2011; Ligtenberg et al., 2009; Lynch et al., 2011; Niessen 
et al., 2009). Interestingly, the Del_4.9 variant described 
here and that previously reported (Ligtenberg et al., 2009) 
(GenBank: FJ347525.1) had different breakpoints, al-
though involving the same Alu sequences, and our family 
had no known Dutch ancestry.
For three out of four deletions, we had evidence in both 
normal and tumor colon tissues, of EPCAM/MSH2 fusion 
transcripts. These were concomitant to MSH2 promoter 
methylation, which acted as a first hit for gene inactivation.
In all EPCAM deleted tumors analyzed, MSH2/MSH6 
IHC nuclear expression was always abnormal. In three cases 
the loss of nuclear MSH2 staining was compatible with a 
large somatic deletion of the locus. A peculiarity was the 
MSH2 cytoplasmic staining detected in two cases. This aber-
rant localization is similar to that described in a previous re-
port of a larger deletion involving both EPCAM and the first 
two exons of MSH2 (Sekine et al., 2017), and is consistent 
with the production of the alternative in‐frame fusion tran-
scripts, predicted to be translated into chimeric proteins. It is 
tempting to speculate that the fusion with EPCAM alters the 
intrinsic capability of MSH2 to form a functional complex 
with MSH6, which is responsible for MSH2/MSH6 nuclear 
shuttling (Gassman et al., 2011).
Somatic EPCAM/MMR second hits could be identi-
fied only in three out of six EPCAM deletion‐associated 
tumors. The sub‐optimal quality of FFPE DNA from sam-
ples CFS825T and CFS1475T prevented NGS testing, 
so somatic MSH2 point‐mutations cannot be excluded. 
Instead, MSH2 deficiency remains unexplained in sample 
CFS395T, in which both MLPA and NGS analyses were 
performed, but neither LOH nor DNA sequence variants 
were detected.
EPCAM deletion carriers typically show high penetrance 
of early onset CRC and a CRC cumulative risk up to 75%; 
compared to MSH2 mutation carriers rarely develop multi-
ple tumors of different histotypes. Moreover, the cumulative 
risk of EC in EPCAM deletion carriers is lower (12% vs. 
51%), although this risk is slightly increased for deletions 
more proximal to the MSH2 locus (Kempers et al., 2011). 
According to previous genotype‐phenotype correlations, 
even in our small dataset EC is absent and the most frequent 
tumor is CRC, with 16 CRCs in eight affected carriers. 
Notably, one duodenal tumor was also recorded, confirm-
ing a previous suggestion of increased risk (Kempers et 
al., 2011), but the data are insufficient for correlating this 
clinical phenotype to particular EPCAM genotypes. Given 
the presence of multiple metachronous CRCs, the gastro‐
intestinal prevention protocols for EPCAM deletion carri-
ers should be focused on colon‐rectum, but surveillance of 
small intestine is also warranted. It is worth noting that EC 
occurrence, even if rare, cannot be excluded, and the gyne-
cologic surveillance is still advised for all women with an 
EPCAM deletion.
This report underscores the importance of EPCAM ge-
netic screening in LS patients, especially in the presence of 
an atypical pattern of MSH2 protein expression in tumors. 
In perspective, a thorough molecular characterization of the 
breakpoints might help in genetic counseling by laying down 
the basis for improved tumor risk estimates.
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